The first patient in Latvia was enrolled on October 1 at Paula Stradiņa Klīniskā universitātes slimnīca in Riga, under the leadership of Principal Investigator Prof. Andrejs Erglis.
Congratulations to Prof. Ērglis and the entire study team for reaching this important milestone.
Sponsored by CERIC and supported by Meril, LEAVE NOTHING BEHIND continues to expand its international reach, with CERC as the CRO supporting the study.
🔗 Learn more: Leave Nothing Behind : DCB strategy with BRS versus BRS strategy | CERC
